Valentín Ortíz-Maldonado, Susana Rives, Maria Castellà, Anna Alonso-Saladrigues, Daniel Benítez-Ribas, Miguel Caballero-Baños, Tycho Baumann, Joan Cid, Enric Garcia-Rey, Cristina Llanos, Montserrat Torrebadell, Neus Villamor, Eva Giné, Marina Díaz-Beyá, Laia Guardia, Mercedes Montoro, Albert Català, Anna Faura, E Azucena González, Marta Español-Rego, Nela Klein-González, Laia Alsina, Pedro Castro, Iolanda Jordan, Sara Fernández, Federico Ramos, Guillermo Suñé, Unai Perpiñá, Josep M Canals, Miquel Lozano, Esteve Trias, Andrea Scalise, Sara Varea, Joaquín Sáez-Peñataro, Ferran Torres, Gonzalo Calvo, Jordi Esteve, Álvaro Urbano-Ispizua, Manel Juan, Julio Delgado
We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001 cells at a dose of 0.4-5 × 106 ARI-0001 cells/kg, initially as a single dose and later split into 3 fractions (10%, 30%, and 60%) with full administration depending on the absence of cytokine release syndrome (CRS). 58 patients were included, of which 47 received therapy: 38 with acute lymphoblastic leukemia (ALL), 8 with non-Hodgkin's lymphoma, and 1 with chronic lymphocytic leukemia...
September 20, 2020: Molecular Therapy